- Wednesday November 4, 2009
- Subscribe Now
The Associated Press
November 11, 2009, 12:30PM ET
Correction: XenoPort-Glaxo drug
NEW YORK
In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for the drug in restless legs syndrome, not neuropathic pain.
Most Popular Stories
- Central Bank Buying Spurs a Gold Rush
- Look Who's Stalking Wal-Mart
- Amazon Paces Holiday Tech Discount Drive
- Tesco Lands Deal to Sell Apple iPhones
- Jim Rogers on Why Gold Is Glittering So Brightly
- Look Who's Stalking Wal-Mart - BusinessWeek
- Jim Rogers on Why Gold Is Glittering So Brightly - BusinessWeek
- Central Bank Buying Spurs a Gold Rush - BusinessWeek
- Behind the Great Stock Rally of 2009 - BusinessWeek
- How Big Pharma Profits from Swine Flu - BusinessWeek
BW Mall - Sponsored Links
- Mutual Funds at Fidelity Benefit from years of mutual fund management experience.
- High interest checking only online! 2.02 APY, FDIC insured, mobile banking and no fee bill pay. Incredible!
- Internet Marketing Bachelor's Degree Learn Effective Internet Marketing Strategies While Earning a Bachelor's Online!
- OppenheimerFunds. Products and Services For A Range Of Financial Goals. Learn More.
- Your Customers Speak Email: Do You? You Already Have What You Need to Maximize ROI: Your Current Customers.
- Buy a link now!
Business Tools
A-Z Index
Lists & Rankings
Blogs
- Apple
- Asia
- Autos
- Branding
- Economy
- Investing
- Management Trends
- Real Estate
- Small Business
- Social Media
- Technology
